Privately-held biotech company focused on protein degradation, Arvinas, has entered into a strategic collaboration with pharma giant Merck & Co (NYSE: MRK).
Arvinas’ novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics. The collaboration will span several years and encompass multiple disease targets across several therapeutic areas.
Financial arrangements have not been disclosed but Arvinas will receive an upfront payment and funding to support Merck-related research and Arvinas could earn up to $434 million if all research, development, regulatory and commercial milestone payments are successfully paid.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze